1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Delayed Swiss Exchange  -  11:30 2022-08-18 am EDT
319.95 CHF   +1.04%
03:03aJemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader
CI
08/17FDA accepts supplemental Biologics License Application for Roche's Polivy combination for people with previously untreated diffuse large B-cell lymphoma
AQ
08/17Sanofi trial failure halts work on breast cancer treatment amcenestrant
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Kenya: Ministry signs agreement to enhance access to breast cancer treatment

06/21/2022 | 03:41am EDT

The Ministry of Health, the National Health Insurance Fund (NHIF) and Roche have today signed Memorandums of Understanding (MOU) making Herceptin- an innovative breast cancer treatment available to all NHIF members without them having to top up the payment in cash. This is the first national access program for cancer medicines in Kenya and an important step to ensuring Kenyan women with breast cancer have access to standard of care treatment. As part of the agreement, Roche will also support capacity building and training of NHIF and Ministry of Health employees by independent, external experts on data management, health economics, pricing and reimbursement approaches. Furthermore, the agreement will see Roche continue to strengthen the screening and early diagnosis of patients as well as the referral pathways to the treatment centers.

Speaking at the signing of today's MOU, Susan Mochache, Principal Secretary, Ministry of Health, said, "Cancer is one of the key public health challenges of our times. 6,000 cases of breast cancer are diagnosed in Kenya each year, causing suffering, emotional trauma and financial stress. The Ministry of Health is already increasing screening and diagnostic services in National and County facilities countrywide to help reduce the burden of breast cancer. Today's MOU with Roche represents the next step of our focus, ensuring that breast cancer patients can now get the care they need through the NHIF without a co-payment. This means that they can focus on their health and well-being and financial strain does not need to affect access."

Breast cancer is the most commonly diagnosed cancer in Kenya, with 6,000 cases diagnosed each year and 2,500 breast cancer-related deaths taking place. The economic burden of breast cancer is substantial and reflects health care spending as well as lost productivity due to morbidity and premature death from cancer. Early detection combined with effective treatment through surgical removal, radiation therapy or medication therapy (hormonal, chemical or biological therapies) can achieve survival probabilities of 90% or higher.

Distributed by APO Group on behalf of Ministry of Health, Kenya.

.

(C) 2022 M2 COMMUNICATIONS, source M2 PressWIRE

All news about ROCHE HOLDING AG
03:03aJemincare Announces Exclusive License Agreement with Genentech to Develop and Commercia..
CI
08/17FDA accepts supplemental Biologics License Application for Roche's Polivy combination f..
AQ
08/17Sanofi trial failure halts work on breast cancer treatment amcenestrant
RE
08/16Genentech - FDA Accepts Supplemental Biologics License Application for Genentech's Poli..
AQ
08/16Swiss Drugmaker Roche Gets US FDA Review for Lymphoma Treatment
MT
08/16FDA Accepts Supplemental Biologics License Application for Genentech's Polivy Combinati..
BU
08/16FDA accepts supplemental Biologics License Application for Roche's Polivy combination f..
GL
08/16U.S. Food and Drug Administration Accepts Supplemental Biologics License Application by..
CI
08/15Novartis fails again to reuse anti-inflammatory drug to treat lung cancer
RE
08/15Roche Unveils New Diagnostic Test for COVID-19 Immune Response
MT
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 64 249 M 67 424 M 67 424 M
Net income 2022 14 824 M 15 557 M 15 557 M
Net Debt 2022 10 272 M 10 779 M 10 779 M
P/E ratio 2022 17,2x
Yield 2022 3,02%
Capitalization 263 B 276 B 276 B
EV / Sales 2022 4,25x
EV / Sales 2023 4,13x
Nbr of Employees 100 920
Free-Float 89,0%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 319,95 CHF
Average target price 374,13 CHF
Spread / Average Target 16,9%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-16.47%273 077
JOHNSON & JOHNSON-2.51%440 598
ELI LILLY AND COMPANY14.66%301 034
PFIZER, INC.-17.73%276 521
ABBVIE INC.4.35%250 080
NOVO NORDISK A/S5.17%239 447